Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...
The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
Early one morning, while checking on a slumbering patient at the Center for Sleep Medicine, Erik St. Louis, M.D., noticed something peculiar. The patient, a woman in her early 60's, had started ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results